PARP1 and Ewing sarcoma: As VIDE protocol is the standard of care for Ewing sarcomas, we analyzed the sensitivity of PF1095 cells to the drugs included in this combination (vincristine, ifosfamide, doxorubicin, and etoposide) and to irinotecan and the PARP inhibitor olaparib (Figure 4A; Supplementary Figure S2).